Lung cancer is a big topic at this year's American Society of Clinical Oncology meeting. It isn't exactly the easiest disease to treat, so any positive data is great news for investors.
The problem for Pfizer is that crizotinib is designed to treat patients who have a certain mutation that only occurs in 4% of lung cancers. Pfizer will be able to charge a premium for the drug, but obtaining $2 billion in sales might be stretching it, given the limited patient population.
Farther back in the pipeline, OXiGENE's
Interested in small companies? Grab this free report from Motley Fool analysts: "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke."
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.